Par Pharmaceutical, Inc. clinical trials
Acquired by Par Health, Nov 10, 2025 · source ↗
The registry lists 36 studies whose lead sponsor is Par Pharmaceutical, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 29, 2017.
Before and after it joined Par Health
- First submitted before Par Pharmaceutical, Inc. became part of Par Health
- 36
- First submitted after Par Pharmaceutical, Inc. became part of Par Health
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Par Pharmaceutical, Inc.36 studies
Something wrong with this grouping? Tell us on the Par Health page.
Studies
Recruiting first, then most recently updated. Showing 36 of 36. All Par Health studies →
- Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic DermatitisCompletedNCT03297502Phase 3
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed ConditionsCompletedNCT00652873Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed ConditionsCompletedNCT00652730Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed ConditionsCompletedNCT00652704Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed ConditionsCompletedNCT01380496Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Leflunomide Tablets Under Fed ConditionsCompletedNCT00653003Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy TubesTerminatedNCT01994642Phase 3
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Propranolol Under Fed ConditionsCompletedNCT00652600Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Tramadol/APAP Tablets Under Fed ConditionsCompletedNCT00652821Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis ExternaTerminatedNCT01910155Phase 3
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated SuspensionTerminatedNCT00637403Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer PatientsTerminatedNCT00637728Phase 3
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated SuspensionTerminatedNCT00637806Phase 3
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food StudyCompletedNCT01380431Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting ConditionsCompletedNCT01380457Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Metronidazole Capsules Under Fed ConditionsCompletedNCT01380522Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Metronidazole Capsules Under Fasting ConditionsCompletedNCT01380509Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fasting ConditionsCompletedNCT01380483Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Comparative Bioavailability Study of Lisinopril Tablets, 10 mgCompletedNCT01375244Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Torsemide Tablets Under Fasting ConditionsCompletedNCT00653549Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting ConditionsCompletedNCT00659074Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Ondansetron 16 mg Orally Disintegrating Tablets Under Fasting ConditionsCompletedNCT00659685Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed ConditionsCompletedNCT00653458Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Torsemide Tablets Under Fed ConditionsCompletedNCT00654043Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting ConditionsCompletedNCT00654277Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Tramadol/APAP Tablets Under Fasting ConditionsCompletedNCT00653315Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Propranolol Under Fasting ConditionsCompletedNCT00653120Phase 2
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting ConditionsCompletedNCT00653380Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Leflunomide Tablets Under Fasting ConditionsCompletedNCT00652665Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Oxandrolone Tablets Under Fasting ConditionsCompletedNCT00652886Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Clonazepam ODT Under Fasting ConditionsCompletedNCT00652912Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Clonazepam Tablets Under Fasting ConditionsCompletedNCT00652639Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting ConditionsCompletedNCT00653055Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting ConditionsCompletedNCT00652795Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting ConditionsCompletedNCT00653419Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health
- Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting ConditionsCompletedNCT00653393Phase 1
Sponsor listed in the registry: Par Pharmaceutical, Inc. · First submitted before Par Pharmaceutical, Inc. became part of Par Health